[Form 4] EyePoint Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Ashford Hospitality Trust, Inc. (NYSE: AHT) filed an 8-K on 11-Jul-2025 announcing that its Board has declared cash dividends on every outstanding series of its preferred stock.

• Quarterly dividends for Q3 2025, payable 15-Oct-2025 to holders of record 30-Sep-2025: Series D $0.5281; Series F $0.4609; Series G $0.4609; Series H $0.46875; Series I $0.46875.
• Monthly dividends (three payments each on 15-Aug, 15-Sep, 15-Oct-2025, record dates 31-Jul, 29-Aug, 30-Sep-2025): Series J $0.16667; Series K $0.17500, $0.17292 or $0.17083 depending on CUSIP; Series L $0.15625; Series M $0.16042.
• Outstanding shares as of 30-Jun-2025: Series J 7,699,923; Series K 747,299; Series L 112,181; Series M 145,232.

The information was furnished under Item 7.01 (Reg FD) and is therefore not considered “filed” for liability purposes.

Insights

Financial Analyst

TL;DR: Routine preferred-stock dividends declared; evidences liquidity but adds no strategic change—impact neutral.

The 8-K confirms Ashford Hospitality Trust continues to meet its cumulative dividend obligations across all preferred series. Maintaining these payments supports the company’s credibility with preferred holders and suggests near-term cash-flow stability. However, because the amounts exactly match stated coupon rates and no common-stock dividend or new capital actions were announced, the filing does not alter the overall investment thesis. The disclosure is therefore largely administrative and should have limited effect on valuation or credit outlook.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lurker Nancy

(Last) (First) (Middle)

C/O EYEPOINT PHARMACEUTICALS, INC.

480 PLEASANT STREET

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
EyePoint Pharmaceuticals, Inc. [ EYPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/10/2025		M		11,111	A	$0.00	216,547	D
Common Stock								126,889	I	By Family Trust(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0.00	07/10/2025		M			11,111	(2)	(2)	Common Stock	11,111	$0.00	11,112	D

Explanation of Responses:

1. These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

2. The restricted stock units vests in three ratable annual installments beginning July 10, 2024.

Remarks:

	/s/ Ron Honig, Attorney-in-Fact	07/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.